Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (251-260 of 337) with videos related to

Pageof 34
Sort By:
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 16, 2014
The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunityFranziska S Hoffmann, Peer-Hendrik Kuhn, Sarah A Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Pageof 34

Showing results (251-260 of 337) with videos related to

Sort By:
Pageof 34
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 16, 2014
The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunityFranziska S Hoffmann, Peer-Hendrik Kuhn, Sarah A Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
The Lancet. Haematology|August 27, 2021
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna-Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer, et al.
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Pageof 34